Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ligritinib · AB-801

Small molecule · Inhibitor of AXL receptor tyrosine kinase (AXL) · developed by Arcus Biosciences

Phase 1 Most advanced trial (none active)
RCUS Developer
1 Registered trials

What is Ligritinib?

Ligritinib is an orally bioavailable inhibitor that reversibly binds the AXL receptor tyrosine kinase and prevents its activation. It is being studied in advanced cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AB-801
Drug type
Small molecule
Targets
AXL receptor tyrosine kinase (AXL)
Mechanism
Inhibitor of AXL receptor tyrosine kinase (AXL)
Pathways
AXL-mediated signal transduction, tumor cell growth, proliferation and migration, AXL-mediated immunosuppression
Therapy area
Oncology
Developer
Arcus Biosciences, Inc. (RCUS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
8ZHG636DGC

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06120075 Phase 1 Advanced Cancer Completed RCUS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Cancer

Other drugs acting on AXL

More from Arcus Biosciences

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RCUS page.

Follow RCUS, the company behind Ligritinib

See RCUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RCUS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.